Brian S Murphy, MD

Clinical

1. Murphy BS. Infectious diseases versus clinical researchers: Who is winning? Pharmafile Research and Development Guide. September 2011; 52: 34.
2. Scott EG and Murphy BS. Chronic Eosinophilia and Strongyloidiasis. Journal of the Kentucky Medical Association. June 2011; 109:4-6.
3. Hayes JD, Meadows, TJ, Murphy BS, Feola DJ, Shook LA, Ballard HO. Pulmonary function outcomes in bronchopulmonary dysplasia through childhood and into adulthood: Implications for primary care. Primary Care Respiratory Journal. 2011. 20(2): 128-33.
4. Hayes JD, Feola DJ, Murphy BS. Eradication of Pseudomonas aeruginosa in an adult CF patient. American Journal of Health System-Pharmacy. 2011. 68(4): 319-322.

Research

1. Myint T, R Greenberg, J Ribes, M Al Hassan, BS Murphy. Temporal trends, clinical characteristics and outcome of histoplasmosis in a tertiary care center in Kentucky, 2000-2009. Journal of the International Association of Providers of AIDS Care. July 2013.

2. Cory TJ, SE Birket, BS Murphy, D Hayes, MI Anstead, J Kanga, RJ Kuhn, HM Bush, DJ Feola. Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis. Submitted to Journal of Cystic Fibrosis. July 2013.
3. Kurkjian CJ, BS Murphy, DJ Feola, BA Garvy. Alternatively activated macrophages contribute to resolution of Pneumocystis in neonatal mice. Submitted to Journal of Immunology. July 2013.

4. Breslow JM, CJ Kurkjian, JP McGillis, TJ Cory, SE Birket. LM Schutzmann, BS Murphy, BA Garvy, DJ Feola. Pneumocystis infection reprograms the activation state of pulmonary macrophages. Submitted to Journal of Immunology. July 2013.

5. Solomkin JS, Ristagno RL, Das AF, Rotstein OD, Wilson SE, Murphy BS, Severin KS, and Bruss JB. Source Control Review in Clinical Trials of Anti-Infective Agents in Complicated Intra-abdominal Infections. Clinical Infectious Disease 2013. 56(12:1765-73).

6. Cory T, Susan B, Murphy BS, Mattingly C, Breslow-Deckman J, Feola D. Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 2012. 68(4):840-51.

Abstract Presentations

Murphy BS, N Kaplan, B Hafkin. Treatment of ABSSSI due to Staphylococcus with AFN-12520000 in a Phase 2a Clinical Trial Resulted in High Rates of Response at Day 3 and at the Test of Cure. ICAAC 2013, Denver, Colorado.

Myint T, RN Greenberg, JA Ribes, BS Murphy, and M Al-Hasan. Temporal trends, clinical characteristics and outcomes for Histoplasmosis in an endemic tertiary care center in Kentucky, 2000-2009. For presentation at South Central Association for Clinical Microbiologists 2013 Spring Meeting, Plymouth, MI. Poster #3.

Murphy BS and B Hafkin. A phase 2, open-label, multicenter study of the safety, tolerability and efficacy of oral AFN-12520000 in the treatment of acute bacterial skin and skin structure infections (ABSSSI) due to staphylococci. European Society of Clinical Microbiology and Infectious Diseases (ECCMID). April 2013, Berlin, Germany.